3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
3
Neoplasm Metastasis
3
Glioblastoma
3
Central Nervous System Neoplasms
3
Sarcoma
2
Rectal Neoplasms
2
Melanoma
2
Gliosarcoma
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Somatostatinoma
1
Solitary Fibrous Tumor, Pleural
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Pheochromocytoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Interventions
aldesleukin
26
Sunitinib
25
Interferon-alpha
21
Everolimus
18
Sorafenib
16
Cyclophosphamide
16
Filgrastim
13
Bevacizumab
13
Nivolumab
11
Gemcitabine
11
Interleukin-2
10
Axitinib
10
fludarabine phosphate
9
Gene Expression Profiling
9
temsirolimus
8
Peripheral Blood Stem Cell Transplantation
8
Doxorubicin
8
pembrolizumab
7
Radiotherapy
6
Radiosurgery
6
Polymerase Chain Reaction
6
Ipilimumab
6
Carboplatin
6
sargramostim
5
Ifosfamide
5
Fluorouracil
5
Erlotinib Hydrochloride
5
Capecitabine
5
Bortezomib
5
atezolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Kidney Neoplasms
×
vatalanib
×
Clear all
NCT00303732
2016-03-03
PTK/RAD
Duke University
Phase 1
Completed
37 enrolled